Short-term clinical outcome of repeated minimally invasive surfactant therapy in very premature infants
Objective To evaluate short-term clinical outcome of repeated minimally invasive surfactant therapy(rMIST)in very(extremely)premature infants.Methods 183 extremely premature infants who gave birth,received two doses of pulmonary surfactant(PS)treatment and received the first dose of PS by MIST in The Affiliated Yancheng Maternal and Child Health Hospital of Yangzhou University from January 2016 to November 2022 were selected as study subjects.According to administration method of the second dose of PS,they were divided into repeated MIST group(rMIST group)and endotracheal intubation group(ETT group).The clinical data and prognostic indexes of very premature infants and their mothers in the two groups were analyzed and compared.Independent sample t-test or continuity-adjusted Chi-square test were used for statistical analysis,and multifactorial Logistic regression was used to analyze correlation between rMIST and bronchopulmonary dysplasia(BPD).Results The maximum fraction of inspired oxygen(FiO2)before PS in the rMIST group was significantly lower than that in the ETT group,and the interval between the first and the second doses of PS was significantly longer than that in the ETT group(t=3.779 and 4.115 respectively,both P<0.05).The mechanical ventilation rate,ventilation time and the incidence of BPD in the rMIST group were significantly lower than those in the ETT group,and the differences were significant(t/x2=4.825,1.599 and 4.546 respectively,all P<0.05).Multifactorial Logistic regression analysis showed that repeated MIST(aOR=0.863,95%CI:0.162-0.913)was protective factor of BPD,while utility of mechanical ventilation(aOR=2.002,95%CI:1.114-4.116)and mechanical ventilation time(aOR=2.058,95%CI:1.011-5.026)were risk factors for BPD.Conclusion Repeated implementation of MIST on extremely premature infants can reduce rate of mechanical ventilation and may reduce the incidence of BPD.